Evidence map›Paper›PMID 41806221›Full record

ArticleBritish journal of haematology2026

Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

Gian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin, Anna Maria Frustaci, Ilaria Scortechini, Francesca Romana Mauro, Francesco Angotzi, Marina Motta, Lydia Scarfò, Andrea Mengarelli and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Gian Matteo RigolinHematology Section, St. Anna University Hospital, Ferrara, Italy.
Stefano SodduGIMEMA Foundation, Rome, Italy.
Riccardo DondolinDivision of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
Anna Maria FrustaciDipartimento di Ematologia, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.ORCID https://orcid.org/0000-0003-2587-7901
Ilaria ScortechiniHematology Clinic, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Francesca Romana MauroHematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.ORCID https://orcid.org/0000-0003-2425-9474
Francesco AngotziHematology Unit, Department of Medicine, University of Padova, Padova, Italy.
Marina MottaHematology, ASST Spedali Civili di Brescia, Brescia, Italy.
Lydia ScarfòMedical School, Università Vita-Salute San Raffaele, Milan, Italy.
Andrea MengarelliHematology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Annamaria GiordanoUnit of Hematology and Stem Cell Transplantation, AOUC Policlinico, and Department of Precision and Regenerative Medicine and Ionian Area, "Aldo Moro" University School of Medicine, Bari, Italy.
Sara MartinelliStruttura Semplice Dipartimentale di Ematologia Ospedale S. Chiara, Trento, Italy.
Caterina PattiU.O.C. di Oncoematologia, Ospedali Riuniti Villa Sofia-Cervello, Palermo, Italy.
Paolo SportolettiHematology and Clinical Immunology Section, Department of Medicine and Surgery, Centre for Hemato-Oncological Research (CREO), University of Perugia, Perugia, Italy.ORCID https://orcid.org/0000-0002-5630-9862
Alessandro SannaHematology Unit, Department of Oncology, AOU Careggi, Florence, Italy.ORCID https://orcid.org/0000-0002-5015-381X
Nilla MaschioOnco Hematology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.ORCID https://orcid.org/0000-0003-3420-3204
Rossella RiccioniEmatologia ATNO, Struttura Semplice Ematologia Sud, Ospedale di Livorno, Livorno, Italy.
Clara Virginia ViganòU.O.S. Oncoematologia, Dipartimento Oncologico, ASST Lecco Ospedale Manzoni, Lecco, Italy.
Agostino TafuriDepartment of Clinical and Molecular Medicine and Hematology, Sant'Andrea-University Hospital-Sapienza, University of Rome, Rome, Italy.
Alfonso PiciocchiGIMEMA Foundation, Rome, Italy.ORCID https://orcid.org/0000-0001-8648-885X
Paola FaziGIMEMA Foundation, Rome, Italy.
Stefano LuminariDivision of Hematology, Azienda Unità Sanitaria Locale-IRCCS Reggio Emilia Italy; CHIMOMO Department, University of Modena and Reggio Emilia, Reggio Emilia, Italy.ORCID https://orcid.org/0000-0001-8446-2285
Andrés J M FerreriUnit of Lymphoid Malignancies, Department of Onco-Haematology, IRCCS Ospedale San Raffaele, Milan, Italy.
Guido GiniHematology Clinic, Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy.
Paolo GhiaMedical School, Università Vita-Salute San Raffaele, Milan, Italy.
Antonio CuneoHematology Section, St. Anna University Hospital, Ferrara, Italy.

Funding

AstraZeneca
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

B‐cell non‐Hodgkin lymphomachronic lymphocytic leukaemiaCOVID‐19pre‐exposure prophylaxis

Identifiers

PMID41806221
PMCPMC13176514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.